Cargando…

Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study

BACKGROUND/AIM: The aim of this study was to evaluate the effects of a 6-month treatment regimen with exenatide on the lipid profile, high-sensitivity C-reactive protein (hsCRP), carotid intima media thickness (CIMT), visceral adiposity, and nonalcoholic fatty liver disease (NAFLD), all of which are...

Descripción completa

Detalles Bibliográficos
Autores principales:	KÖSEOĞLU, Derya, KOPARAL, Salih Suha, ÖZDEMİR BAŞER, Özden, BERKER, Dilek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Scientific and Technological Research Council of Turkey 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991851/ https://www.ncbi.nlm.nih.gov/pubmed/32892547 http://dx.doi.org/10.3906/sag-2004-154

Ejemplares similares

Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience
por: Imga, Narin Nasiroglu, et al.
Publicado: (2019)

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus
por: Bawa, Tarunika, et al.
Publicado: (2013)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus
por: Pereira, Marie, et al.
Publicado: (2017)

Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
por: Voukali, Maria, et al.
Publicado: (2014)

Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
por: Khan, Muhammad, et al.
Publicado: (2015)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2014)

Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports
por: Censani, Marisa, et al.
Publicado: (2015)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2019)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus
por: Guclu, Metin, et al.
Publicado: (2017)

Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
por: Song, Jinfang, et al.
Publicado: (2022)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
por: Zhang, Jie, et al.
Publicado: (2022)

A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes
por: Htike, Zin Z., et al.
Publicado: (2012)

The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review
por: Ojo, Omorogieva
Publicado: (2016)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
por: Song, Sun Ok, et al.
Publicado: (2013)

PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients
por: Liu, Xu, et al.
Publicado: (2023)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
por: Raman, Vandana S., et al.
Publicado: (2010)

Comparison of the clinical and sonographic effects of ultrasound therapy, extracorporeal shock wave therapy, and Kinesio taping in lateral epicondylitis
por: ÖZMEN, Tarık, et al.
Publicado: (2021)

Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long‐acting release
por: Takenaka, Kenchi, et al.
Publicado: (2019)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study
por: Li, Boyu, et al.
Publicado: (2020)

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
por: Ratner, Robert, et al.
Publicado: (2011)

Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients
por: Hong, Ju-Young, et al.
Publicado: (2016)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
por: Basson, Mickael, et al.
Publicado: (2017)

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study
por: Hu, Yanjin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bbnvi22dr49p5ssgrj67pefetp